Capsaicin inhibits benzo(a)pyrene-induced lung carcinogenesis in an in vivo mouse model

Inflammation Research

Volumn 61, Issue 11, 2012, Pages 1169-1175

  Anandakumar, P ^a   Kamaraj, S ^a   Jagan, S ^a   Ramakrishnan, G ^a   Asokkumar, S ^a   Naveenkumar, C ^a   Raghunandhakumar, S ^a   Devaki, T ^a  

^a UNIVERSITY OF MADRAS   (India)

Author keywords

Benzo(a)pyrene; Capsaicin; Inflammatory mediators; Lung cancer; Mast cells

Indexed keywords

BENZO[A]PYRENE; CAPSAICIN; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; ERYTHROCYTE COUNT; HEMOGLOBIN BLOOD LEVEL; IN VIVO STUDY; LEUKOCYTE COUNT; LUNG CARCINOGENESIS; MALE; MAST CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TREATMENT RESPONSE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZO(A)PYRENE; BLOOD CELL COUNT; CAPSAICIN; CYCLOOXYGENASE 2; INTERLEUKIN-6; LUNG NEOPLASMS; MALE; MAST CELLS; MICE; NF-KAPPA B; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84868144302     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-012-0511-1     Document Type: Article

References (44)

1. Magesh V, Jayapal PV, Selvendiran K, Ekambaram G, Sakthisekaran D. Antitumour activity of crocetin in accordance to tumor incidence, antioxidant status, drug metabolizing enzymes and histopathological studies. Mol Cell Biochem. 2006;287:127-35.
2. Stephen S, Pramod Upadhaya, Mingyao Wang, Robin Bliss L, Edward Mcintee J, Patrick Kenney MJ. Inhibition of lung tumorigenesis in A/J mice by N-acetyl-S-(N-2-phenethylthiocarbamoyl)-l-cysteine and myo-inositol, individually and in combination. Carcinogenesis. 2002;29:1455-61.
3. Hans peter W, Deuter M, Imilda E. Chemoprevention of tobacco smoke induced lung carcinogenesis in mice. Carcinogenesis 2000; 21:977-982.
4. Anto RJ, Mukhopadyah A, Denning K, Aggarwal BB. Curcumin induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis. 2002;23:143-50.
5. Holzer P. Capsaicin: cellular targets, mechanisms of action, and selectivity for thin sensory neurons. Pharmacol Rev. 1991;43(2):143-201.
6. Holzer P. The pharmacological challenge to the transient receptor potential vanilloid-1 (TRPV1) nocisensor. Br J Pharmacol. 2008;155(8):1145-62.
7. Pinter E, Helyes Z, Szolcsányi J. Inhibitory effect of somatostatin on inflammation and nociception. Pharmacol Ther. 2006;112(2):440-56.
8. Modly CE, Das M, Don PS, Marcelo CS, Mukhtar H, Bickers DR. Capsaicin as an in vitro inhibitor of benzo(a)pyrene metabolism and its DNA binding in human and murine keratinocytes. Drug Metab Dispos. 1986;14:413-6.
9. Zhang Z, Hamilton SM, Stewart C, Strother A, Teel RW. Inhibition of liver microsomal cytochrome P-450 activity and metabolism of the tobacco-specific nitrosamine NNK by capsaicin and ellagic acid. Anticancer Res. 1993;13:2341-6.
10. Teel RW, Zhang Z, Uynh H, Hamilton SM. Effects of capsaicin on the metabolic activation of heterocyclic amines and on cytochrome P450 1A2 activity in hamster liver microsomes. Proc Am Assoc Cancer Res. 1997;38:363.
11. De AK, Ghosh JJ. Capsaicin pretreatment protects free radical induced rat lung damage on exposure to gaseous chemical lung irritants. Phytother Res. 1993;7:87-9.
12. Anandakumar P, Kamaraj S, Jagan S, Ramakrishnan G, Naveenkumar C, Asokkumar S, Devaki T. Capsaicin alleviates the imbalance in xenobiotic metabolizing enzymes and tumor markers during experimental lung tumorigenesis. Mol Cell Biochem. 2009;331(1-2):135-43.
13. Anandakumar P, Kamaraj S, Jagan S, Ramakrishnan G, Devaki T. Effect of capsaicin on glucose metabolism studied in experimental lung carcinogenesis. Nat Prod Res. 2009;23(8):763-74.
14. Anandakumar P, Kamaraj S, Jagan S, Ramakrishnan G, Devaki T. Chemopreventive task of capsaicin against benzo(a)pyrene induced lung cancer in Swiss albino mice. Basic Clin Pharmacol Toxicol. 2009;104(5):360-5.
15. Dacie JV, Lewis SM. Practical haematology. 7th ed. ELBS with Churchill Living stone: England; 1991. pp 37-85.
16. D'Armour FE, Blood FR, Belden DA. The manual for laboratory works in mammalian physiology. 3rd ed. The University of Chicago Press: Illinois, Chicago; 1965.
17. Wintrobe MM, Lee GR, Boggs DR, Bithel TC, Athens JW, Foerster J. Clinical Hematology. 5th ed. Les & Febiger: Philadelphia; 1961.
18. Ranieri G, Labriola A, Achille G, Florio G, Zito AF, Grammatica L, et al. Microvessel density, mast cell density and thymidine phosphorylase expression in oral squamous carcinoma. Int J Oncol. 2002;21(6):1317-23.
19. Ramakrishnan G, Elinos-Baez CM, Jagan S, Augustine TA, Kamaraj S, Anandakumar P, Devaki T. Silymarin downregulates COX-2 expression and attenuates hyperlipidemia during NDEA-induced rat hepatocellular carcinoma. Mol Cell Biochem. 2008;313:53-61.
20. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999;91:1616-34.
21. Brown JM. The hypoxic cell: a target for selective cancer therapyEighteenth Bruce F Cain memorial award lecture. Cancer Res. 1999;59:5863-70.
22. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Caner Inst. 2001;93:266-76.
23. Gangar SC, Sandhir R, Koul A. Effects of Azadirachta indica on certain hematological parameters during benzo(a)pyrene induced murine forestomach tumorigenesis. Eur Rev Med Pharmacol. 2010;14:1055-72.
24. Ariztia EV, Lee CJ, Gogoi R, Fishman DA. The tumor microenvironment: key to early detection. Crit Rev Clin Lab Sci. 2006;43:393-425.
25. Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol. 2004;14:433-9.
26. Noguchi M, Hiwatashi N, Liu Z, Toyota T. Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease. Gut. 1998;43:203-9.
27. Ben-Baruch A. Host microenvironment in breast cancer development: inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Res. 2003;5:31-6.
28. Tselepis C, Perry I, Dawson C, Hardy R, Darnton SJ, McConkey C, Stuart RC, Wright N, Harrison R, Jankowski JA. Tumour necrosis factor-a in Barrett's oesophagus: a potential novel mechanism of action. Oncogene. 2002;21:6071-81.
29. Rose-John S, Schooltink H. Cytokines are a therapeutic target for the prevention of inflammation-induced cancers. Recent Results Cancer Res. 2007;174:57-66.
30. Kai H, Kitadai Y, Kodama M, Cho S, Kuroda T, Ito M, Tanaka S, Ohmoto Y, Chayama K. Involvement of proinflammatory cytokines IL-1b and IL-6 in progression of human gastric carcinoma. Anticancer Res. 2005;25:709-13.
31. Schneider MR, Hoeflich A, Fischer JR, Wolf E, Sordat B, Lahm H. Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells. Cancer Lett. 2000;151:31-8.
32. Chung YC, Chang YF. Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol. 2003;83:222-6.
33. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol. 2006;72:1605-21.
34. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, et al. Increased expression of cyclooxygenase-2 occurs frequently in human lung cancer, specifically in adenocarcinomas. Cancer Res. 1998;58:3761-4.
35. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 1997;57:1276-80.
36. Yip-Schneider MT, Barnard DS, Billings SD, Cheng L, Heilman DK, Lin A, Marshall SJ, Crowell PL, Marshall MS, Sweeney CJ. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis. 2000;21:139-46.
37. Naylor MS, Stamp GW, Foulkes WD, Eccles D, Balkwill FR. Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest. 1993;91:2194-206.
38. Lawrence T. Inflammation and cancer: a failure of resolution? Trends Pharmacol Sci. 2007;28:162-5.
39. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431:461-6.
40. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res. 2006;4:221-33.
41. Melendez AJ, Harnett MM, Pushparaj PN, et al. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med. 2007;13:1211-8.
42. Theoharides TC, Conti P. Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol. 2004;25:235-41.
43. Tan S-Y, Fan Y, Luo H-S, Shen Z-X, Guo Y, Zhao L-J. Prognostic significance of cell infiltrations of immunosurveillance in colorectal cancer. World J Gastroenterol. 2005;11:1210-4.
44. Takanami I, Takeuchi K, Naruke M. Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer. 2000;15:2686-92.